Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression

Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression

Abstract Background To evaluate the effects of long-acting somatostatin analogue (SSA) therapy on 68Ga-DOTA-octreotate (GaTate) uptake at physiological and metastatic sites in neuroendocrine tumour (NET) patients. Methods Twenty-one patients who underwent GaTate PET/CT before and after commencement...

Full description

Bibliographic Details
Main Authors: Martin H. Cherk, Grace Kong, Rodney J. Hicks, Michael S. Hofman
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Cancer Imaging
Subjects:
Somatostatin
Octreotate
Ga-68
Neuroendocrine tumour
Positron emission tomography
DOTATATE
Online Access:http://link.springer.com/article/10.1186/s40644-018-0136-x

Internet

http://link.springer.com/article/10.1186/s40644-018-0136-x

Similar Items